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Viruses are a common threat to cellular life, not the least to bacteria and archaea who constitute the
majority of life on Earth. Consequently, a variety of mechanisms to resist virus infection has evolved. A
recent discovery is the adaptive immune system in prokaryotes, a type of system previously thought to
be present only in vertebrates. The system, called CRISPR-Cas, provide sequence-speciﬁc adaptive im-
munity and fundamentally affect our understanding of virusehost interaction. CRISPR-based immunity
acts by integrating short virus sequences in the cell's CRISPR locus, allowing the cell to remember,
recognize and clear infections. There has been rapid advancement in our understanding of this immune
system and its applications, but there are many aspects that await elucidation making the ﬁeld an
exciting area of research. This review provides an overview of the ﬁeld and highlights unresolved issues.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For each cell on Earth there are about ten viruses [1]. Viruses are
key factors in the ecology and evolution of life by acting as preda-
tors and facilitators of genetic exchange. Not surprising, an array of
countermeasures can be observed in their hosts, generally grouped
into innate and adaptive immune systems. Innate (non-speciﬁc)
systems recognize certain generic features of infection. Restriction-
modiﬁcation and abortive infection are examples of such innate
systems in prokaryotes. Adaptive systems, on the other hand, have
the ability to learn to recognize speciﬁc features of pathogens. In
humans, B and T cells can learn to recognize proteins and other
structures in order to destroy pathogens and infected cells. Due to
the complexity of that system, the demonstration of an adaptive
immune system in prokaryotes [2] was a surprise. The prokaryotic
system, based on a region of DNA called Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR; [3]), is a largely
stand-alone system that is capable of functioning in an individual
cell, a necessity for organisms that often display unicellular
behavior. The CRISPR-Cas system targets DNA or RNA as a way of
protecting against viruses and other mobile genetic elements [2,4].r Biology, Uppsala University,
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B.V. This is an open access article uThe CRISPR locus, ﬁrst observed in Escherichia coli [5], is present
in about 84% of archaea and 45% of bacteria according to the most
recent update of the CRISPRdb [6]. The difference in prevalence
could be affected by sampling bias as almost twenty times more
bacteria than archaea have been analyzed. The CRISPR is an array of
short repeated sequences separated by spacers with unique se-
quences. The CRISPR can be found on both chromosomal and
plasmid DNA. The spacers are often derived from nucleic acid of
viruses and plasmids, an observation that gave rise to the idea that
CRISPRs are part of an anti-virus system [7e9]. By adding new
spacers new viruses can be recognized. The spacers are used as
recognition elements to ﬁnd matching virus genomes and destroy
them.
CRISPR activity requires the presence of a set of CRISPR-
associated (cas) genes, usually found adjacent to the CRISPR, that
code for proteins essential to the immune response [2,10]. Since the
genome is modiﬁed in the process of spacer acquisition, offspring
inherit the protection. New spacers are usually added at one side of
the CRISPR, making the CRISPR a chronological record of the viruses
the cell and its ancestors have encountered.
The CRISPR-Cas mediated defense process can be divided into
three stages (Fig. 1). The ﬁrst stage, adaptation, leads to insertion of
new spacers in the CRISPR locus (Fig 2). In the second stage,
expression, the system gets ready for action by expressing the cas
genes and transcribing the CRISPR into a long precursor CRISPRnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The key steps of CRISPR-Cas immunity. 1) Adaptation: insertion of new spacers
into the CRISPR locus. 2) Expression: transcription of the CRISPR locus and processing
of CRISPR RNA. 3) Interference: detection and degradation of mobile genetic elements
by CRISPR RNA and Cas protein(s).
Fig. 2. Model of the adaptation in the Type I-E system. There are two types of spacer
acquisition, naïve and primed. Both require the presence of a PAM and are dependent
on the Cas1eCas2 complex. The Cas1eCas2 complex recognizes the CRISPR and likely
prepares it for spacer integration. Naïve spacer acquisition occurs when there is no
previous information about the target in the CRISPR. Primed spacer acquisition re-
quires a spacer in the CRISPR locus that matches the target DNA and the presence of
Cas3 and the Cascade complex. Primed acquisition results in insertion of more spacers
from same mobile genetic element. PAM ¼ Protospacer Adjacent Motif.
D. Rath et al. / Biochimie 117 (2015) 119e128120RNA (pre-crRNA). The pre-crRNA is subsequently processed into
mature crRNA by Cas proteins and accessory factors (Fig. 3). In the
third and last stage, interference, target nucleic acid is recognized
and destroyed by the combined action of crRNA and Cas proteins
(Fig. 3).
This review provides an overview of the mechanism of the
CRISPR-mediated immunity as well as its diversity, the virus
countermeasures, evolution and ecology. Naturally occurring
functions not related to immunity and the impressive recent
development of genetic tools based on CRISPR-Cas and their ap-
plications are also covered.
2. Diversity, ecology and evolution of the CRISPR-Cas systems
The length and sequence of repeats and the length of spacers are
well conserved within a CRISPR locus, but may vary between
CRISPRs in the same or different genomes. Repeat sequences are in
the range of 21 bp to 48 bp, and spacers are between 26 bp and 72
bp [3,6,7]. The observed variation is perhaps not surprising given
how widespread the system is. The number of spacers within a
CRISPR locus vary widely; from a few to several hundreds [6]. Ge-
nomes can have single or multiple CRISPR loci and in some species
these loci can make up a signiﬁcant part of the chromosome. In
Methanocaldococcus sp. FS406-22 (with eighteen CRISPRs and 191
spacers) and Sulfolobus tokodaii str. 7 (with ﬁve CRISPRs and 458
spacers) the CRISPRs make up about 1% of the genome [11]. Not all
CRISPR loci have adjacent cas genes and instead rely on trans-
encoded factors. Another feature associated with CRISPR loci is
the presence of a conserved sequence, called leader, located up-
stream of the CRISPR with respect to direction of transcription. Thepresence of these leader sequences was initially observed in
Methanocaldococcus jannaschii, Archaeoglobus fulgidus and Meth-
anothermobacter thermautotrophicus but has subsequently been
found in many other species [3].
The Cas proteins are a highly diverse group. Many are predicted
or identiﬁed to interact with nucleic acids; e.g. as nucleases, heli-
cases and RNA-binding proteins [12]. The Cas1 and Cas2 proteins
are involved in adaptation (see Section 3) and are virtually
Fig. 3. Model of crRNA processing and interference. (A) In Type I systems, the pre-crRNA is processed by Cas5 or Cas6. DNA target interference requires Cas3 in addition to Cascade
and crRNA. (B) Type II systems use RNase III and tracrRNA for crRNA processing together with an unknown additional factor that perform 50 end trimming. Cas9 targets DNA in a
crRNA-guided manner. (C) The Type III systems also use Cas6 for crRNA processing, but in addition an unknown factor perform 30 end trimming. Here, the Type III Csm/Cmr complex
is drawn as targeting DNA, but RNA may also be targeted.
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associated with certain types of CRISPR-Cas systems. The diversity
of Cas proteins, presence of multiple CRISPR loci and frequent
horizontal transfer of CRISPR-Cas systems make classiﬁcation a
complex task. The most adopted classiﬁcation identiﬁes Type I, II
and III CRISPR-Cas systems, with each having several subgroups
[13]. Different types of CRISPR-Cas systems can co-exist in a single
organism. Recently, a Type IV systemwas proposed, which contain
several Cascade genes but no CRISPR, cas1 or cas2 [14]. Type IV
complex would be guided by protein-DNA interaction, not by
crRNA, and constitutes an innate immune system preset to attack
certain sequences.
The Type I systems are deﬁned by the presence of the signature
protein Cas3, a protein with both helicase and DNase domains
responsible for degrading the target [15]. Currently, six subtypes of
the Type I system are identiﬁed (Type I-A through Type I-F) that
have a variable number of cas genes. Apart from cas1, cas2 and cas3,
all Type I systems encode a Cascade-like complex. Cascade bindscrRNA and locates the target, andmost variants are also responsible
for processing the crRNA. Cascade also enhances spacer acquisition
in some cases. In the Type I-A system, Cas3 is a part of the Cascade
complex.
The Type II CRISPR-Cas systems encode Cas1 and Cas2, the Cas9
signature protein and sometimes a fourth protein (Csn2 or Cas4).
Cas9 assists in adaptation, participates in crRNA processing and
cleaves the target DNA assisted by crRNA and an additional RNA
called tracrRNA [16e20]. Type II systems have been divided into
subtypes II-A and II-B but recently a third, II-C, has been suggested
[21,22]. The csn2 and cas4 genes, both encoding proteins involved in
adaptation [2,19,20], are present in Type II-A and the Type II-B,
respectively, while Type II-C lacks a fourth gene.
The Type III CRISPR-Cas systems contain the signature protein
Cas10 with unclear function. Most Cas proteins are destined for the
Csm (in Type III-A) or Cmr (in Type III-B) complexes, which are
similar to Cascade [23e25]. Interestingly, while all Type I and II
systems are known to target DNA, Type III systems target DNA and/
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exclusively found in bacteria while the Type I and Type III systems
occur both in bacteria and archaea [13].
The large number of genomes with detected CRISPRs could be
used as an argument for its importance as defense mechanism.
However, the CRISPR-Cas systems are probably mobile genetic el-
ements that frequently transfers horizontally, which also contrib-
utes to their high prevalence. The CRISPR-Cas systems are not only
beneﬁcial, they have a maintenance and production cost and the
risk of self-targeting (which could kill the host) reduces the value of
the system. As an example, E. coli contains a CRISPR-Cas system that
is efﬁciently silenced by H-NS [26], which could be interpreted as
inactivation conferring a selective advantage. On the other side of
the scale, in an analysis of acid mine drainage, extreme CRISPR
diversity was observed where no two sampled individual cells had
the same spacers [27]. The viruses in the acid mine drainage used
recombination to diversify rapidly, making any but the most recent
spacers lack a target [28].
Experiments on CRISPR dynamics have been performed mainly
in Streptococcus thermophilus, and they indicate that spacer sam-
pling is not random as a small number of spacers dominates and
their relative abundances oscillate rapidly [29]. Other ﬁndings
indicate that phages can still replicate in populations with one but
not two spacers targeting them [30].
There is some light starting to be shed over the evolution of
CRISPR-Cas systems. It has been hypothesized that the Type IV
system is similar to an ancestral innate immune system that gained
adaptive ability by associating with a transposon-like element
containing cas1 and cas2 [14]. The transposon was domesticated
but retained the terminal inverted repeats that formed the ances-
tral CRISPR repeats. Repeats were then duplicated and spacers
added by the action of Cas1 [31]. The process eventually resulted in
the formation of Type I and III CRISPR-Cas systems. The Type II
systems are suggested to have been formed by a replacement of theFig. 4. Hypothesis for CRISPR-Cas system evolution. A casposon inserts adjacent to a Cascad
loses genes and the terminal inverted repeats (TIRs) expand into a CRISPR cluster to eventua
is initiated when a transposon containing cas9 replaces the Cascade genes. Unlabeled geneCascade genes by cas9 (Fig. 4). Cas9 is also linked to mobile genetic
elements as it resembles transposon-encoded proteins [14,21].
3. CRISPR adaptation
The adaptation phase provides the genetic memory that is a pre-
requisite for the subsequent expression and interference phases
that neutralize the re-invading nucleic acids. The insertion of new
spacers has been experimentally demonstrated in several CRISPR-
Cas subtypes; Type I-A (Sulfolobus solfataricus [32], and Sulfolobus
islandicus [33]), I-B (Haloarcula hispanica [34]), I-E (E. coli [35e37])
and I-F (Pseudomonas aeruginosa [38] and Pectobacterium atro-
septicum [39]) and Type II-A (S. thermophilus [2,19,40] and a
Streptococcus pyogenes system expressed in Staphylococcus aureus
[20]). There are two types of spacer acquisition; naïve, when the
invader has not been previously encountered, and primed, when
there is a pre-existing record of the invader in the CRISPR (Fig. 2)
[41].
Although spacer acquisition is observed, the mechanism is only
partly understood. Conceptually, the process can be divided into
two steps: protospacer selection and generation of spacer material
followed by integration of the spacer into the CRISPR array and
synthesis of a new repeat. Occasional deletion of spacers is required
to limit the size of the CRISPR, but there is little knowledge of the
mechanism or frequency of such events.
The key factors in spacer integration are Cas1 and Cas2. This
function was suggested early as the proteins are ubiquitous but
dispensable for interference [10]. This was later conﬁrmed by
overexpression of Cas1 and Cas2 from a Type I-E system in E. coli,
which resulted in spacer integration even in the absence of all other
Cas proteins [36]. Both Cas1 and Cas2 are nucleases [42e44] and
mutations in the active site of Cas1 abolishes spacer integration in
E. coli [36,37]. Cas1 and Cas2 from E. coli form a complex where one
Cas2 dimer binds two Cas1 dimers. Formation of the complex ise operon with protein-based non-adaptive targeting ability. The casposon subsequently
lly form Type I and III CRISPR-Cas systems. The Type II CRISPR-Cas system development
tic elements are of variable nature.
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dispensable. Cas1 preferentially binds CRISPR DNA in a Cas2-
dependent manner, further supporting a direct role in spacer
acquisition [45]. It could be speculated that the Cas1-Cas2 complex
both transport the spacer material and perform spacer integration,
which would explain the need for the many Cas1 subunits in the
complex. A few additional factors are known to be required for
spacer acquisition: Cas9, Csn2 and tracrRNA in Type II-A [2,19,20]
and Cas4 in Type I-B [34]. The roles of tracrRNA, Csn2 and Cas4
are unclear but Cas9 probably guides the integration machinery.
Host polymerases, ligases and recombination proteins are likely to
perform generic steps in the adaptation, as such factors can be
found in every host cell.
Spacer selection appears guided by certain sequence elements
in the target. Analysis of target sequences has revealed a shortmotif
next to the target sequence called protospacer adjacent motif
(PAM) that is crucial for discrimination between self and non-self
[46] (see Section 5). While initially thought to be important only
for interference, the PAM also has a role in spacer acquisition. This is
supported by the fact that most newly acquired spacers have a PAM
next to their protospacer [35,37]. In the Type II-A system, Cas9 is
responsible for identifying the PAM asmutations that disable Cas9's
PAM recognition result in acquisition from protospacers without
PAM [20]. In Type I-E, PAM recognition during spacer acquisition
may be different as they are indicated to be identiﬁed by Cas1-Cas2
alone [36]. However, Cascade increases the frequency of correct
PAMs for inserted spacers [35,37]. In Type I-E, spacers are prefer-
entially incorporated from extra-chromosomal elements [37],
which is demonstrated to be a result of a connection between
adaptation and replication [129]. In Type II-A, spacer acquisition
may not be biased toward extra-chromosomal elements as cells
with nuclease-deﬁcient Cas9 demonstrate unbiased spacer sam-
pling and an increased rate of spacer acquisition in one study [19].
Acquisition of self-targeting spacers would not readily be observed
with functional Cas9, as the potential lethality of the events would
result in the cells being lost from the population.
Once located, it is not known if the protospacer is copied or cut
out of the target. The production of spacer material could be linked
to other defense systems, such as the restriction-modiﬁcation
system [47], similar to primed spacer acquisition (see below).
Such coupling may facilitate the systems' recognition of “foreign
DNA” or provide the systemwith material suitable for new spacers.
Infection by a phage incapable of reproduction, which e.g. only
packaged a partial viral genome, could act as a vaccine and facilitate
adaptation.
How are spacers actually integrated in the CRISPR array? Cas1
nuclease activity is required for nicking the CRISPR array in E. coli,
and Cas1 is possibly responsible for the integration of the new
spacer [48]. An in vitro study with Type I-E Cas1 and Cas2 conﬁrm
that the complex can insert DNA fragments into a CRISPR array by a
mechanism reminiscent of retroviral integrases and transposases
[31]. Whether or not the mechanism for spacer integration is
conserved between the different systems remains to be
determined.
In both the Type I-E and Type II-A system, it is demonstrated
that parts of the leader and one repeat are required for spacer
integration. Further, the leader-proximal repeat serves as template
for synthesis of the new repeat [36,40], probably by a strand sep-
aration mechanism (Fig. 2). The leader dependence is likely the
cause for the observed polar addition of spacers to the CRISPR [2],
although there are reported exceptions [32]. The palindromic na-
ture of many CRISPR repeats is important to determine the position
and direction of spacer integration into the array [31]. It is indicated
that palindromic repeats form cruciform DNA structures that re-
cruits Cas1 and Cas2 (Fig. 2) [31,48], and such structures are knownto be a target for Cas1 cleavage [42]. Interestingly, in vitro spacer
integration can also be performed at other sequences predicted to
form cruciform structures, in the absence of repeats [31]. Taken
together, spacer integration is directed both by sequence and
structure of the CRISPR.
Adaptation has been shown to be coupled to the interference
machinery through primed spacer acquisition, which occurs when
there is a targeting spacer already present in the CRISPR array. The
interference machinery and a pre-existing spacer accelerate the
acquisition of subsequent spacers from the same target. Primed
spacer acquisition was ﬁrst described in the Type I-E system in
E. coli [37], but has subsequently been reported for I-B in H. his-
panica [34] and I-F in P. atrosepticum [39], but so far not in any Type
II or III system. Priming seems to occur by slightly different pro-
cesses in the described cases but the exact molecular mechanisms
remain unknown. In Type I-F systems, Cas2 is fused to Cas3 [13],
further indicating a direct connection between the adaptation and
interference processes. Interestingly, spacers with several mis-
matches that are incapable of providing protection against the
target still induce primed spacer acquisition [49]. It should be noted
that although Cas9 is required for spacer acquisition in the Type II-A
system, this is not an example of primed spacer acquisition as the
requirement is not dependent on a pre-existing spacer against the
target [20]. The advantages of primed spacer acquisition are
obvious: multiple spacers provide increased resistance against
invading DNA, andmake it more difﬁcult for target to evolve escape
mutants as several sites would need to be changed simultaneously.4. Expression of CRISPR RNA and cas genes
The transcription of the CRISPR-Cas loci to generate a RNA-
protein guide complex follows a general theme in most organ-
isms but also displays several type-speciﬁc differences (Fig. 3). All
systems transcribe the CRISPR locus; process the RNA with Cas ri-
bonucleases and form a CRISPR ribonucleoprotein (crRNP) com-
plex. In some species, e.g. E. coli, Pyrococcus furiosus and Sulfolobus
sp., CRISPR transcription initiates in the leader region [26,50e52].
The leader contains promoter elements and binding sites for reg-
ulatory proteins, in addition to elements important for spacer
integration (see Section 3). A long primary transcript, the pre-
crRNA, is generated and may contain a series of secondary struc-
tures (hairpins) if the CRISPR contains palindromic repeats. The
pre-crRNA is processed into smaller units corresponding to a single
spacer ﬂanked by partial repeats. The Cas protein responsible for
the processing, and if that protein is part of a complex or not, varies
with the subtype. Even when the three CRISPR-Cas types naturally
co-exist they do not process each other's pre-crRNA [53].
Overall comparison of the three types of CRISPR-Cas systems
shows that Type I and III systems share similarities in pre-crRNA
processing as well as in the structures of the crRNP complexes
formed (Fig. 3A and C). All Type I and III systems utilize a Cas6
protein for pre-crRNA processing except Type I-C, which employs
Cas5d [54]. In Type I-E systems, e.g. in E. coli, the pre-crRNA is
cleaved in a metal-independent mechanism by the Cas6e
endoribonuclease [10].
The Cas6e and the crRNA are key components of the E. coli
Cascade complex, which also contains one copy of Cse1, two copies
of Cse2, one copy of Cas5e and six copies of Cas7 [55]. Cascade has a
sea-horse shape where the Cas7 proteins provide a helical back-
bone along which the crRNA is displayed [56] held in place by b-
hairpin thumbs extending from Cas7. Cas5e and Cas6e anchor the 50
and 30 ends of the crRNA to opposite sides of Cascade [57e59]. One
study has demonstrated that Cascade could be assembled in cells
lacking crRNA and subsequently loaded with crRNA in vitro [60].
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do not need to be an integrated process.
In Type III systems, pre-crRNA maturation also involves a
sequence-speciﬁc processing step mediated by Cas6 [61,62], fol-
lowed by a ruler-based sequence-unspeciﬁc crRNA trimming at the
30 end to yield mature crRNAs with a deﬁned 50 end and variable 30
end [61,63]. Structural analysis of Type III-A (Csm) and Type III-B
(Cmr) complexes reveal a helical backbone, similar to that of
Cascade, against which the crRNA is aligned. The 50 end of the
crRNA is likely anchored by Csm1-Csm4/Cmr2-Cmr3 and the 30 end
by Csm5/Cmr1-Cmr6 [23e25].
Type II systems employ a very different mechanism for crRNA
biogenesis where processing is dependent on host RNase III and a
trans-encoded small RNA (tracrRNA) that base pairs with the pre-
crRNA [16] (Fig. 3B). In addition, Type II processing also requires
the Cas9 protein [16,18] though its exact role is unclear. Another
distinct feature of the Type II systems is the 50 trimming of the
crRNA by an unknown nuclease while the crRNA-tracrRNA remains
bound to the Cas9 [18].
5. Interference
The principle of target interference by CRISPR-Cas systems is
that crRNA bound to Cas protein(s) locates the corresponding
protospacer to trigger degradation of the target (Fig. 3). The
degradation is performed by speciﬁc Cas nucleases [10,17].
In Type I systems Cascade locates the target DNA but the Cas3
nuclease/helicase is needed for interference [10,13,64]. Cas3 can be
recruited by Cascade upon target binding or, in the case of Type I-A,
be a permanent part of Cascade. In the Type I-A system the Cas3
nuclease and helicase domains are encoded as separate genes [13].
Bioinformatics analysis also suggests a split cas3 gene for I-B sys-
tems [13,65], but experimental data indicate that this is not always
the case [34]. However, in all Type I systems the two domains act
together to processively degrade the double stranded DNA target
[66e68].
In Type I and II systems interference requires the presence of a
PAM sequence and perfect protospacer-crRNA complementarity in
the so-called seed region, located adjacent to the PAM [69e71]. The
presence of a PAM triggers “non-self activation”, which prevents
the systems from attacking its own CRISPR locus.
In Cascade, the Cas7 thumbs holding the crRNA kink every sixth
base out of position and consequently mismatches at those posi-
tions do not affect target binding [49,57e59]. A few additional
mismatches outside the seed region are tolerated and do not affect
interference [49,69]. Cascade can interact non-speciﬁcally with
DNA [55] and scans for PAMs and seed regions, with the PAM
suggested to be detected by Cse1 [72]. Seed-region base pairing is
followed by pairing the rest of the crRNA, leading to displacement
of the non-bound DNA strand and formation of an R-loop [55] and
also here Cse1 plays an important role [73]. The binding of the
crRNA to the target causes conformational changes in Cascade and
the target DNA [56,66] that could be the trigger for Cas3 recruit-
ment. Cas3 then nicks the target DNA and proceeds with progres-
sive degradation of the target [66] while Cascade presumably
dissociates and is ready for action again.
Type II systems require only the Cas9 protein for interference
but unlike Type I and III systems it needs not just crRNA, but also a
tracrRNA bound to Cas9 and the crRNA to perform target recogni-
tion and degradation [16]. Cas9 structures from S. pyogenes and
Actinomyces naeslundii reveal separate lobes for target recognition
and nuclease activity, accommodating the crRNA-DNA heterodu-
plex in a positively charged groove at their interface [74,75]. The
recognition lobe is important for binding crRNA and target DNA,
and the nuclease lobe contains the HNH and RuvC nucleasedomains that cleave the complementary and non-complementary
strands of the target, respectively [74]. As the crRNA-induced
reorientation of structural lobes facilitates DNA substrate binding,
loading of crRNA is proposed as a key step in Cas9 activation [75].
The Csm complex in Type III-A typically includes six different
proteins but the nuclease is not yet identiﬁed [23]. The Cmr com-
plex in III-B includes six or seven different proteins [23,24,63] and
the Cmr4 protein cleaves the target [76e78]. Early ﬁndings indi-
cated that Csm complexes target DNA [62] and Cmr complexes
targets RNA [4,25,79], but amore complex picture is now emerging.
In Thermus thermophilus and S. thermophilus the Csm complex
targets RNA, and in T. thermophilus, which harbors both Type III-A
and III-B systems, the Csm and Cmr complexes share crRNA
[80,81]. Targeting of RNA and DNA by the same Cmr complex has
been demonstrated in S. islandicus [82,83]. No PAMs are detected
for Type III systems, instead the discrimination between self and
non-self is achieved by an extension of crRNA base pairing into the
repeat region of host DNA, which results in “self inactivation”, a
fundamentally different process to the PAM recognition used by
Type I and II systems [84].
An additional aspect of interference has been demonstrated for
a Type III-A system in S. aureus, where the system is prevented from
attacking un-transcribed targets such as lysogenized phages [85].
Such a system makes sense since it prevents potential degradation
of the host's own chromosome. The mechanism behind the system
is not known and it remains to be determined if this is awidespread
feature of CRISPR-Cas systems.
6. Anti-CRISPR mechanisms
Just as cells have developed multiple strategies to counteract
viruses, the viruses have developed countermeasures to these
strategies. Several distinct mechanisms for counteracting CRISPR-
Cas systems have been described. The most basic way for viruses
to escape CRISPR-Cas activity is by randommutagenesis that affects
key bases in the interaction with the crRNA or the PAM recognition
[69,86].
A more reﬁned countermeasure has been discovered in
P. aeruginosa phages that encode several proteins affecting the ac-
tivity of Type I-E and I-F systems. The functions of the proteins are
not clear but they do not appear to affect expression of Cas proteins
or the crRNA. Likely, they interfere with activity of CRISPR-Cas
complexes [87,88].
In an unusual turn of events, it has been demonstrated that the
CRISPR-Cas system can be used by viruses to promote infection.
Vibrio cholerae ICP1 phages carry a Type I-F CRISPReCas system that
targets a host locus, PLE, containing an anti-phage system [89].
After entry of the phage genome into the cell, the viral crRNAs and
cas genes are expressed to enable infection of the V. cholerae host. If
the host or the CRISPR is engineered so that the viral CRISPR-Cas
system no longer matches the PLE, the ability of ICP1 to infect is
largely lost. The few phages that manage to infect do so by having
picked up a new spacer targeting the host locus, demonstrating
that the viruses can use the full adaptive potential of the CRISPR-
Cas system.
7. CRISPR-Cas involvement in processes other than immunity
Although most studies on CRISPR-Cas systems points to its pre-
dominant role as protection against invading genetic material, its
involvement in other cellular processes such as regulation of
virulence, genome evolution and DNA repair is becoming increas-
ingly evident. In most cases the processes behind the alternative
functions are not well known and further investigations are
required to bring clarity to the matter.
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single-stranded and branched DNA species, replication forks and 50
ﬂaps. Further, Cas1 interacts with RecB, RecC and RuvB suggesting a
role in DNA repair, [42] but the RecBCD complex also enhance
spacer acquisition [129]. It has also been reported that CRISPR-Cas
is triggered by accumulation of misfolded proteins in the mem-
brane of E. coli, suggesting a role in handling accumulation of
defective proteins [90].
Several examples of CRISPR-Cas involvement in gene regula-
tion have been reported. In Listeria monocytogenes, a CRISPR
without cas genes targets the host chromosome, and the crRNAs
increase the level of target RNA by stabilizing it [91]. Another
example is Francisella novicida where a Type II CRISPR-Cas system
mediates repression of an endogenous lipoprotein gene. The
repression is required for full virulence of F. novicida in mice as the
lipoprotein otherwise triggers an innate immune response in the
mouse. The repression is achieved by the combined action of Cas9,
tracrRNA and a novel RNA, called scaRNA, and is suggested to work
by binding a region spanning the target gene's start codon [92].
Expression of the Cas9 protein in Campylobacter jejuni lacking
CRISPR loci has been demonstrated to increase virulence [93] and
in Legionella pneumophila Cas2 is required for infection of
amoebae in a CRISPR-independent manner [94]. In P. aeruginosa,
CRISPR is involved in inhibition of bioﬁlm formation. The inhibi-
tion requires cas1, a lysogenized DMS3 phage and a spacer
matching the phage [95].
A CRISPR locus targeting the host chromosome can contribute to
genome evolution.While such events are generally lethal, surviving
mutants often have large-scale genomic rearrangements. For
example, crRNA targeting a pathogenicity island in P. atrosepticum
yielded mutants with ~100 kb deletions spanning the genomic is-
land [96].Fig. 5. Examples of basic CRISPR applications. (A) The sgRNA directs Cas9 cleavage of the cor
DNA damage: Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR). N
used to make speciﬁc changes to the target region by providing a designed repair template t
and Cas9. In absence of Cas3, Cascade can be used to block access of RNA polymerase to a ge
manner. sgRNA ¼ single guide RNA.These reports raise interesting questions with regard to the
evolution of CRISPR-Cas function. It is not clear if the additional
roles developed prior to the function as an immune system, in
parallel with it, or from it. Biological processes are usually in a state
of ﬂux, so the “additional roles” may be examples of evolution by
tinkering.
8. CRISPR applications
CRISPRs were used for applied purposes before their functions
in host defensewere known, particularly by taking advantage of the
heterogeneity of CRISPRs among isolates that are otherwise
isogenic. This was the basis for a typing system for Mycobacterium
tuberculosis, useful for determining diagnosis and epidemiology. An
initial PCR-based method [97] was further developed into a
hybridization-based method, called spoligotyping, suitable for
routine use and high-throughput genotyping [98]. CRISPR typing
has also been developed for Yersinia pestis [9,99], Salmonella
[100,101] and Corynebacterium diphtheriae [102].
In dairy industry, Danisco (part of DuPont) are marketing starter
cultures for improved cheese production and other applications.
The cultures contain bacteria that have CRISPRs with improved
resistance to phages that can cause production problems. The
company realized the importance of CRISPR-Cas early, and was the
ﬁrst to demonstrate its function as an immune system [2].
However, the best known applications come from the devel-
opment of the Type II system into powerful genetics tools for
eukaryotic cells. Particularly the demonstration that crRNA and
tracrRNA can be combined in to a single guide RNA (sgRNA) paved
the way for this development [18]. Unlike Cas3, which processively
degrades the target, Cas9 produces a single double-stranded break
in the DNA, an important feature of a gene-editing tool. Themethodresponding target to initiate gene editing. In eukaryotic cells, two main pathways repair
HEJ removes bases, often causing a frameshift and inactivation of the gene. HDR can be
hat becomes inserted in the damaged region. (B) and (C): Gene silencing using Cascade
ne, without damaging the target. Nuclease-deﬁcient Cas9 can be exploited in a similar
D. Rath et al. / Biochimie 117 (2015) 119e128126makes use of DNA repair pathways in eukaryotic cells to provide
two ways to make genetic alterations (Fig. 5A). The ﬁrst relies on
Non-Homologous End Joining (NHEJ) that joins the cut ends but in
the process often deletes a few bases, which may cripple the gene
product, or cause a frameshift that inactivates it. In the second,
Homology Directed Repair (HDR) is used to repair the damaged
allele using another piece of DNA with homology to the target. By
providing a DNA element that can be inserted by recombination,
any type of insertion, deletion or change in sequence can be ach-
ieved [103,104]. These approaches have previously been demon-
strated using ZFNs and TALENs [105], but Cas9 is simple to use and
re-target, and can easily be used to modify several targets simul-
taneously. The main limitation is the need for a PAM adjacent to the
target. In the short time that has passed since the initial demon-
stration, Cas9 have been used for genome editing in virtually all
commonly studied eukaryotes, fromyeast to humans [106]. In some
of those species precision genetic alteration has never been
possible before. A suite of Cas9-basedmethods has been developed,
e.g. genetic screening [107] and programmable RNA recognition
and cleavage [108]. Off-target effects, where Cas9 interacts with an
unintended target, are a concern [109] but strategies for prediction
and prevention are being developed [110].
The therapeutical potential of Cas9 has been demonstrated. Cas9
has been developed as an antimicrobial agent that can be used to
speciﬁcally target antibiotic-resistant and/or highly virulent strains
of bacteria [111,112]. Gene therapy applications have also been
demonstrated by repairing the cftr gene in cultured cells from
human cystic ﬁbrosis patients [113], by curing dominant cataract
disorder and Duchenne muscular dystrophy by altering DNA in
mouse germ-line cells [114,115], and by curing hereditary tyrosi-
nemia in adult mice [116]. Cas9 also holds potential for treatment of
viral infections, as demonstrated for HIV [117,118] and hepatitis B
[119]. A short version of Cas9 have been demonstrated to be
deliverable by Adeno-associated virus, greatly facilitating its use in
somatic gene therapy [130]. Another important milestone was the
ﬁrst primate with precise genetic modiﬁcations [120], a result of
gene editing in embryos. The ﬁnding allows for development of
disease models in animals very similar to humans. A similar
approach could be used to alter DNA in human embryos to prevent
non-complex hereditary diseases, but also to attempt alteration of
complex traits, which has triggered extensive ethical discussion
[131].
CRISPR-Cas systems have also been developed for programma-
ble gene regulation. Both Cascade and a nuclease-deﬁcient Cas9
mutant (dCas9) can be used for gene silencing by interfering with
RNA polymerase binding or elongation [121e124] (Fig. 5B and C).
By fusing dCas9 with a transcriptional activation domain or a
repressor, transcriptional activation or repression can be achieved
[125e127]. By adding multiple activating domains strong induction
can be achieved [128]. Genome-wide application of this approach
can be used for screening, as demonstrated by the identiﬁcation of
genes that allow melanoma cancer cells to escape treatment.
9. Outlook
The ﬁeld of CRISPR research has developed rapidly. Much
knowledge has been gained, and the ﬁeld is attracting an increasing
amount of attention. However, for several key questions we have
only partial knowledge, particularly with respect to the mechanism
of spacer integration. Other outstanding questions are the
connection between interference and adaptation in primed spacer
acquisition. The reason for the frequent horizontal transfer of
CRISPR also remains to be understood, as do the regulation of the
CRISPR-Cas systems, and the evolution of the system. Other topics
that deserve further attention are the ecological role of CRISPR,countermeasures to CRISPR-Cas systems and the role of CRISPRs in
non-immunity processes. Applied use of Cas9 is now routine in
many research labs around the world, and its popularity continues
to increase. New and better applications will be developed, and in a
not-so-distant futurewewill probably seemedicinal use of CRISPR-
Cas systems.
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